SUMMARY Two cDNA probes, cf23a and cf56a, identify deletions of selected exons in about 50% of our DMD/BMD patients. We have estimated the most likely order of the 11 exons detectable with both probes with respect to the different extensions of the deletions. In one of our BMD pedigrees, the observed deletion could be traced in the affected males through three generations. This result shows that with the use of cDNA probes detecting deletions, the only risk of error in genomic prenatal diagnosis is the general high frequency of new mutations for DMD/BMD. This is important progress in diagnosis compared to the 2 to 5% risk of misdiagnosis 'because of crossing over events using conventional linkage analysis with bridging or intragenic probes. The first prenatal diagnosis of an unaffected fetus of a woman who is a DMD carrier according to ultrasound examination is described. In one of our DMD males, the cDNA probe cf56a detects a deletion breakpoint. His sister also shows the altered band and is therefore a DMD carrier, while his mother has a totally normal band pattern. The interpretation of this observation could be either germline mosaicism or two identical new mutations. The identification of deletion breakpoints is a new diagnostic strategy, especially for carrier determination, which excludes misdiagnosis owing to crossing over events and the problems of dosage estimation. It is, however, limited by the low frequency of breakpoints detectable with cDNA probes. Therefore, the generation of new intron probes in this region is an important goal.
Duchenne muscular dystrophy (DMD) and its clinically milder allelic form, Becker muscular dystrophy (BMD), are the most common X linked recessive genetic disorders affecting about one in 3000 males. DNA diagnosis has resulted in dramatic progress in carrier detection and prenatal analysis for affected families.1-3 However, since up to now it has been predominantly based on linkage analyses, its reliability was limited by the possibility of crossing over events. This has caused difficulties in decision making for pregnant women, particularly in prenatal diagnosis.
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Results
We searched for deletions in affected males from 13 BMD families with the cDNA probes cf23a and cf56a. In four of these families a deletion was detectable with cf23a. Twenty-one DMD males out of a total of 45 showed a deletion with the cDNA probes cf23a an,d cf56a (13/cf23a, 14/cf56a, 6/cf23a and cf56a). Different hybridisation patterns of these deletion patients are shown in fig 1. Fig 2 sum Prenatal diagnosis based on a deletion with cDNA probes was not possible because no DMD male is alive in this family. The woman, who was not prepared to accept an error of 2 to 10% in the prenatal diagnosis, requested termination of pregnancy after the cytogenetic determination of a male fetus. The DNA hybridisation pattern of the fetal material in a PstI digest with cf56a shows a deletion of three exons. Therefore, we concluded that the fetus was affected. This result can be used as a reference' for the DNA analysis of further male pregnancies of this woman.
In one case (lane 13, fig la) Obviously the main field for deletion analysis is in prenatal diagnosis, while carrier determination suffers from the problems of dosage analysis with a risk of misdiagnosis of about 5%, comparable to that of linkage analysis. This limitation could be overcome by identifying deletion breakpoints, detectable by a size change of hybridisation bands, but in general such breakpoints are so far away from the exons that cDNA probes can detect them only in a few cases. Therefore, the isolation of specific intron probes is necessary for a broader application of breakpoint detection in carrier determination of DMD/BMD.
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